Insider Selling: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Insider Sells $18,669.75 in Stock

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) insider James Kihara sold 1,095 shares of ACADIA Pharmaceuticals stock in a transaction on Wednesday, March 26th. The shares were sold at an average price of $17.05, for a total transaction of $18,669.75. Following the completion of the sale, the insider now directly owns 21,275 shares of the company’s stock, valued at approximately $362,738.75. The trade was a 4.89 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

James Kihara also recently made the following trade(s):

• On Monday, February 24th, James Kihara sold 475 shares of ACADIA Pharmaceuticals stock. The shares were sold at an average price of $19.96, for a total value of $9,481.00.

ACADIA Pharmaceuticals Stock Down 0.7 %

ACADIA Pharmaceuticals stock opened at $17.07 on Friday. The business has a 50 day moving average price of $18.34 and a two-hundred day moving average price of $17.03. ACADIA Pharmaceuticals Inc. has a 12 month low of $14.15 and a 12 month high of $20.68. The stock has a market cap of $2.85 billion, a price-to-earnings ratio of 21.88 and a beta of 0.43.

Analyst Ratings Changes

A number of research analysts recently weighed in on ACAD shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $28.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Thursday, February 27th. Morgan Stanley reissued an “equal weight” rating and issued a $20.00 price target on shares of ACADIA Pharmaceuticals in a research report on Friday, March 7th. HC Wainwright reaffirmed a “buy” rating and set a $27.00 price objective on shares of ACADIA Pharmaceuticals in a report on Thursday, February 27th. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 target price on shares of ACADIA Pharmaceuticals in a report on Thursday, February 27th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on shares of ACADIA Pharmaceuticals in a report on Tuesday, February 11th. They set a “hold” rating and a $22.00 price target for the company. Eight equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, ACADIA Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $23.93.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Point72 Asset Management L.P. bought a new stake in ACADIA Pharmaceuticals in the 4th quarter valued at $40,935,000. SG Americas Securities LLC boosted its position in shares of ACADIA Pharmaceuticals by 380.3% during the 4th quarter. SG Americas Securities LLC now owns 2,483,731 shares of the biopharmaceutical company’s stock valued at $45,576,000 after acquiring an additional 1,966,607 shares in the last quarter. Norges Bank bought a new stake in ACADIA Pharmaceuticals in the fourth quarter valued at about $25,555,000. Renaissance Technologies LLC raised its position in ACADIA Pharmaceuticals by 204.2% in the fourth quarter. Renaissance Technologies LLC now owns 1,226,533 shares of the biopharmaceutical company’s stock worth $22,507,000 after purchasing an additional 823,333 shares in the last quarter. Finally, Two Sigma Advisers LP lifted its stake in ACADIA Pharmaceuticals by 160.8% during the fourth quarter. Two Sigma Advisers LP now owns 1,263,200 shares of the biopharmaceutical company’s stock worth $23,180,000 after purchasing an additional 778,900 shares during the period. 96.71% of the stock is currently owned by institutional investors and hedge funds.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.